Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage

Fig. 1

Changes in alanine transaminase before and at the end of the study period

Bars are the median (25–75%). * p < 0.05, *** p < 0.001 between 0 and 52 weeks (Wilcoxon’s signed-rank test for within-group comparisons, and Mann-Whitney U-test for changes between groups). Light and dark green bars represent 0 and 52 weeks in the pemafibrate group, and white and gray bars represent 0 and 52 weeks in the control group. ALT, alanine aminotransaminase; ULN, upper limit of normal, Pema, pemafibrate, Ctrl, control, NS, not significant

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us